A case report of de novo immune thrombocytopenic purpura (ITP) following COVID-19-mRNA vaccination: 2-year clinical follow up

After vaccination with mRNA vaccines, several cases of autoimmune diseases have been reported. We presented a case report of an adult male patient, without any previous report of thrombocytopenia or other hematologic disorders, who developed a chronic paucisymptomatic or mild ITP secondary to SARS-CoV-2 m-RNA vaccine. The patient received the first and second doses of mRNA BNT162b2 vaccine (June/2021), the first booster dose of mRNA-1273 (November/2021), and the second booster dose of mRNA BNT162b2 (June/2022). Thrombocytopenia was documented after each vaccination. After corticoids therapy was implemented, the patient improved. However, cycling thrombocytopenia was documented until August/2023 (mean: 103 x109 platelets/L). Version 2 of the file includes results from a blood count in 2017, which shows that the patient did not have platelet counts less than 100x109 platelets/L, as well as results from other blood counts performed after vaccinations until May 2024.